eCQM QICore Content Implementation Guide
2025.0.0 - CI Build
eCQM QICore Content Implementation Guide, published by cqframework. This guide is not an authorized publication; it is the continuous build for version 2025.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/cqframework/ecqm-content-qicore-2025/ and changes regularly. See the Directory of published versions
Official URL: https://madie.cms.gov/Measure/CMS104FHIRSTKDCAntithrombotic | Version: 0.9.003 | |||
Active as of 2025-06-20 | Responsible: The Joint Commission | Computable Name: CMS104FHIRSTKDCAntithrombotic | ||
Other Identifiers: Short Name: CMS104FHIR (use: usual, ), UUID:4f57e4a2-097b-45f8-9c85-91b35ea92dc1 (use: official, ), UUID:3e24cf04-e7a8-4f7d-b9bc-3c3e3b1b39b6 (use: official, ), Publisher: 104FHIR (use: official, ) | ||||
Copyright/Legal: Measure specifications are in the Public Domain LOINC(R) copyright 2004-2024 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2024 International Health Terminology Standards Development Organisation. ICD-10 copyright 2024 World Health Organization. All Rights Reserved. |
Ischemic stroke patients prescribed or continuing to take antithrombotic therapy at hospital discharge
Metadata | |
---|---|
Title | Discharged on Antithrombotic TherapyFHIR |
Version | 0.9.003 |
Short Name | CMS104FHIR |
GUID (Version Independent) | urn:uuid:4f57e4a2-097b-45f8-9c85-91b35ea92dc1 |
GUID (Version Specific) | urn:uuid:3e24cf04-e7a8-4f7d-b9bc-3c3e3b1b39b6 |
CMS Identifier | 104FHIR |
Effective Period | 2026-01-01 through 2026-12-31 |
Steward (Publisher) | The Joint Commission |
Developer | The Joint Commission |
Description | Ischemic stroke patients prescribed or continuing to take antithrombotic therapy at hospital discharge |
Copyright | Measure specifications are in the Public Domain LOINC(R) copyright 2004-2024 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2024 International Health Terminology Standards Development Organisation. ICD-10 copyright 2024 World Health Organization. All Rights Reserved. |
Disclaimer | These performance measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications. The measures and specifications are provided without warranty. |
Rationale | The effectiveness of antithrombotic agents in reducing stroke mortality, stroke-related morbidity and recurrence rates has been studied in several large clinical trials. While the use of these agents for patients with acute ischemic stroke and transient ischemic attacks continues to be the subject of study, substantial evidence is available from completed studies. Data at this time suggest that antithrombotic therapy should be prescribed at discharge following acute ischemic stroke to reduce stroke mortality and morbidity if no contraindications exist. For patients with a stroke due to a cardioembolic source (e.g., atrial fibrillation, mechanical heart valve), warfarin is recommended unless contraindicated. In recent years, novel oral anticoagulant agents (NOACs) have been developed and approved by the U.S. Food and Drug Administration (FDA) for stroke prevention and may be considered as an alternative to warfarin for select patients. Anticoagulation therapy is not generally recommended for secondary stroke prevention in patients presumed to have a non-cardioembolic stroke Anticoagulants at doses to prevent venous thromboembolism are insufficient antithrombotic therapy to prevent recurrent ischemic stroke or transient ischemic attack (TIA). |
Clinical Recommendation Statement | Clinical trial results suggest that antithrombotic therapy should be prescribed at discharge following acute ischemic stroke to reduce stroke mortality and morbidity if no contraindications exist |
Citation |
CITATION - Adams, H., Adams, R., del Zoppo, G., et al. (2005, April). Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update—A scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke, 36(4): 916-923. |
Citation |
CITATION - Adams, H. P., Jr., del Zoppo, G., Alberts, M. J., et al. (2007, May). Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Stroke, 38(5), 1655-1711. |
Citation |
CITATION - Albers, G. W, Amarenco, P., Easton, J. D., et al. (2001). Antithrombotic and thrombolytic therapy for ischemic stroke. Chest, 119, 300-320. |
Citation |
CITATION - Albers, G. W., Amarenco, P., Easton, J. D., et al. (2004, September). Antithrombotic and thrombolytic therapy for ischemic stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 126(3), 483S-512S. |
Citation |
CITATION - Antiplatelet Trialists’ Collaboration. (1994, January 8). Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ, 308(6921), 81-106. |
Citation |
CITATION - Antithrombotic Trialists’ Collaboration. (2002, January 12). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ, 324(7329), 71-86. |
Citation |
CITATION - Bhatt, D. L., Fox, K. A., Hacke, W., et al. (2006, April 20). Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine, 354(16), 1706-1717. |
Citation |
CITATION - Brott, T. G., Clark, W. M., Fagan, S. C., et al. (2000). Stroke: The first hours. Guidelines for acute treatment. Washington, DC: National Stroke Association. |
Citation |
CITATION - Canadian Cooperative Study Group. (1978, July 13). A randomized trial of aspirin and sulfinpyrazone in threatened stroke. New England Journal of Medicine, 299(2), 53-59. |
Citation |
CITATION - CAPRIE Steering Committee. (1996, November 16). A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 348(9038), 1329-1339. |
Citation |
CITATION - Centers for Disease Control and Prevention. (2009, May 1). Prevalence and most common causes of disability among adults—United States, 2005. Morbidity and Mortality Weekly Report, 58(16), 421-426. |
Citation |
CITATION - Chen, Z. M., Sandercock, P., Pan, H. C., et al. (2000, June). Indications for early aspirin use in acute ischemic stroke: A combined analysis of 40,000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke, 31(6), 1240-1249. |
Citation |
CITATION - Coull, B. M., Williams, L. S., Goldstein, L. B., et al. (2002, July). Anticoagulants and antiplatelet agents in acute ischemic stroke: Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a Division of the American Heart Association). Stroke, 33(7), 1934-1942. |
Citation |
CITATION - Diener, H. C., Bogousslavsky, J., Brass, L. M., et al. (2004, July). Aspirin and lopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet, 364(9431), 331-337. |
Citation |
CITATION - Dutch Tia Trial Study Group. (1991, October 31). A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. New England Journal of Medicine, 325(18), 1261-1266. |
Citation |
CITATION - Eccles, M., Freemantle, N., & Mason, J. (1998, April 25). North of England Evidence-Based Guideline Development Project: Guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. BMJ, 316(7140), 1303-1309. |
Citation |
CITATION - ESPRIT Study Group, Halkes, P. H., van Gijn, J., et al. (2006, May 20). Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial. Lancet, 367(9523), 1665-1673. |
Citation |
CITATION - ESPS Group. (1987, December 12). The European Stroke Prevention Study (ESPS): Principal end-points. Lancet, 2(8572), 1351-1354. |
Citation |
CITATION - Farrell, B., Godwin, J., Richards, S., et al. (1991, December). The United Kingdom Transient Ischaemic Attack (Uk-Tia) Aspirin Trial: Final results. Journal of Neurology, Neurosurgery, and Psychiatry, 54(12), 1044-1054. |
Citation |
CITATION - Gaspoz, J. M., Coxson, P. G., Goldman, P. A., et al. (2002, June 6). Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. New England Journal of Medicine, 346(23), 1800-1806. |
Citation |
CITATION - Gent, M., Blakely, J. A., Easton, J. D., et al. (1989, June 3). The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1(8649), 1215-1220. |
Citation |
CITATION - Gorelick, P. B., Richardson, D., Kelly, M., et al. (2003, June 11). Aspirin and ticlopidine for prevention of recurrent stroke in black patients: A randomized trial. JAMA, 289(22), 2947-2957. |
Citation |
CITATION - Guyatt, G. H., Akl, E. A., Crowther, M., et al. (2012, February). Executive summary: Antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 141(2 Suppl.), 7S-47S. |
Citation |
CITATION - Guyatt, G., Schunemann, H., Cook, D., et al. (2001, January). Grades of recommendation for antithrombotic agents. Chest, 119(1 Suppl.), 3S-7S. |
Citation |
CITATION - Hass, W. K., Easton, J. D., Adams, H. P., Jr., et al. (1989, August 24). Randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. New England Journal of Medicine, 321(8), 501-507. |
Citation |
CITATION - International Stroke Trial Collaborative Group. (1997, May 31). The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet, 349(9065), 1569-1581. |
Citation |
CITATION - Jauch, E. C., Saver, J. L., Adams, H. P., Jr., et al. (2013). Guidelines for the early management of patients with acute ischemic stroke: A guideline for health care professionals from the American Heart Association/American Stroke Association. Stroke, 44(3), 870-947. |
Citation |
CITATION - Johnson, E. S., Lanes, S. F., Wentworth, C. E., III, et al. (1999, June 14). A metaregression analysis of the dose-response effect of aspirin on stroke. Archives of Internal Medicine, 159(11), 1248-1253. |
Citation |
CITATION - Kennedy, J., Hill, M. D., Ryckborst, K. J., et al. (2007, November). Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): A randomised controlled pilot trial. Lancet Neurology, 6(11): 961-969. |
Citation |
CITATION - Kernan, W. N., Ovbiagele, B., Black, H. R., et al. (2014, May). Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for health care professionals from the American Heart Association/American Stroke Association. Stroke, 45(7), 2160-2223. |
Citation |
CITATION - Powers, W. J., Rabinstein, A. A., Ackerson, T., et al. (2018, January). 2018 guidelines for the early management of patients with acute ischemic stroke: A guideline for health care professionals from the American Heart Association/American Stroke Association. Stroke, 49, e45-e46. |
Citation |
CITATION - Roger, V. L., Go, A. S., Lloyd-Jones, D. M., et al. (2012, January 3). Heart disease and stroke statistics—2012 update: A report from the American Heart Association. Circulation, 125(1), e2-e220. |
Citation |
CITATION - Sacco, R. L., Diener, H. C., Yusuf, S., et al. (2008, September 18). Aspirin and Extended-Release Dipyridamole Versus Clopidogrel for Recurrent Stroke. New England Journal of Medicine, 359(12), 1238-1251. |
Citation |
CITATION - SALT Collaborative Group. (1991, November 30). Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet, 338(8779), 1345-1349. |
Citation |
CITATION - UK-Tia Study Group. (1988, January 30). United Kingdom Transient Ischaemic Attack (UK-Tia) Aspirin Trial: Interim results. British Medical Journal (Clinical Research Ed.), 296(6618), 316-320. |
Citation |
CITATION - Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., ... Williams, L. S. (2021). 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association/American Stroke Association. Stroke, 52(7), e364-e467. https://doi.org/10.1161/STR.0000000000000375 |
Guidance (Usage) | The "Nonelective Inpatient Encounter" value set intends to capture all non-scheduled hospitalizations. This value set is a subset of the "Inpatient encounter" value set, excluding concepts that specifically refer to elective hospital admissions. Non-elective admissions include emergency, urgent and unplanned admissions. The "Medication, Discharge" datatype refers to the discharge medication list and is intended to express medications ordered for post-discharge use. The denominator population includes patients with inpatient hospitalizations and patients from Acute Hospital Care at Home programs, who are treated and billed as inpatients but receive care in their home. This dQM is an episode-based measure. An episode is defined as each inpatient hospitalization or encounter that ends during the measurement period. This FHIR-based measure has been derived from the QDM-based measure: CMS104v14. Please refer to the HL7 QI-Core Implementation Guide (https://hl7.org/fhir/us/qicore/STU6/) for more information on QI-Core and mapping recommendations from QDM to QI-Core STU 6. (https://hl7.org/fhir/us/qicore/STU6/qdm-to-qicore.html). |
Measure Group (Rate) (ID: Group_1) | |
Summary | Ischemic stroke patients prescribed or continuing to take antithrombotic therapy at hospital discharge |
Basis | Encounter |
Scoring | Proportion |
Type | Process |
Rate Aggregation | None |
Improvement Notation | Increased score indicates improvement |
Initial Population |
ID: InitialPopulation_1
Description: Inpatient hospitalizations (non-elective admissions) for patients age 18 and older, discharged from inpatient care with a principal diagnosis of ischemic stroke, ending during the measurement period Logic Definition: Initial Population |
Denominator |
ID: Denominator_1
Description: Equals Initial Population Logic Definition: Denominator |
Denominator Exclusion |
ID: DenominatorExclusion_1
Description: - Inpatient hospitalizations for patients admitted for elective carotid intervention. This exclusion is implicitly modeled by only including non-elective hospitalizations. - Inpatient hospitalizations for patients discharged to another hospital - Inpatient hospitalizations for patients who left against medical advice - Inpatient hospitalizations for patients who expired - Inpatient hospitalizations for patients discharged to home for hospice care - Inpatient hospitalizations for patients discharged to a health care facility for hospice care - Inpatient hospitalizations for patients with comfort measures documented Logic Definition: Denominator Exclusions |
Numerator |
ID: Numerator_1
Description: Inpatient hospitalizations for patients prescribed or continuing to take antithrombotic therapy at hospital discharge Logic Definition: Numerator |
Denominator Exception |
ID: DenominatorException_1
Description: - Inpatient hospitalizations for patients with a documented reason for not prescribing antithrombotic therapy at discharge - Inpatient hospitalizations for patients who receive Prasugrel as an antithrombotic therapy at discharge Logic Definition: Denominator Exceptions |
Supplemental Data Guidance | For every patient evaluated by this measure also identify payer, race, ethnicity and sex; SDE Ethnicity-Patient's Ethnicity: Hispanic or Latino Not Hispanic or Latino SDE Payer-Patient's Payer: Categories of types of health care payer entities as defined by the US Public Health Data Consortium SOP code system SDE Race-Patient's Race: Native Hawaiian or Other Pacific Islander Asian American Indian or Alaska Native Other Race White Black or African American SDE Sex-Patient's Sex: Gender identity restricted to only Male and Female used in administrative situations requiring a restriction to these two categories. |
Supplemental Data Elements | |
Supplemental Data Element |
ID: sde-ethnicity
Usage Code: Supplemental Data Description: SDE Ethnicity Logic Definition: SDE Ethnicity |
Supplemental Data Element |
ID: sde-payer
Usage Code: Supplemental Data Description: SDE Payer Logic Definition: SDE Payer |
Supplemental Data Element |
ID: sde-race
Usage Code: Supplemental Data Description: SDE Race Logic Definition: SDE Race |
Supplemental Data Element |
ID: sde-sex
Usage Code: Supplemental Data Description: SDE Sex Logic Definition: SDE Sex |
Measure Logic | |
Primary Library | CMS104FHIRSTKDCAntithrombotic |
Contents |
Population Criteria
Logic Definitions Terminology Dependencies Data Requirements |
Population Criteria | |
Measure Group (Rate) (ID: Group_1) | |
Initial Population | |
|
|
Denominator | |
|
|
Denominator Exclusion | |
|
|
Numerator | |
|
|
Denominator Exception | |
|
|
Logic Definitions | |
Logic Definition | Library Name: TJCOverall |
|
|
Logic Definition | Library Name: TJCOverall |
|
|
Logic Definition | Library Name: TJCOverall |
|
|
Logic Definition | Library Name: TJCOverall |
|
|
Logic Definition | Library Name: TJCOverall |
|
|
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: SupplementalDataElements |
|
|
Logic Definition | Library Name: CMS104FHIRSTKDCAntithrombotic |
|
|
Logic Definition | Library Name: CMS104FHIRSTKDCAntithrombotic |
|
|
Logic Definition | Library Name: CMS104FHIRSTKDCAntithrombotic |
|
|
Logic Definition | Library Name: CMS104FHIRSTKDCAntithrombotic |
|
|
Logic Definition | Library Name: CMS104FHIRSTKDCAntithrombotic |
|
|
Logic Definition | Library Name: CMS104FHIRSTKDCAntithrombotic |
|
|
Logic Definition | Library Name: CMS104FHIRSTKDCAntithrombotic |
|
|
Logic Definition | Library Name: CMS104FHIRSTKDCAntithrombotic |
|
|
Logic Definition | Library Name: CMS104FHIRSTKDCAntithrombotic |
|
|
Logic Definition | Library Name: CMS104FHIRSTKDCAntithrombotic |
|
|
Logic Definition | Library Name: CMS104FHIRSTKDCAntithrombotic |
|
|
Logic Definition | Library Name: CMS104FHIRSTKDCAntithrombotic |
|
|
Logic Definition | Library Name: CMS104FHIRSTKDCAntithrombotic |
|
|
Logic Definition | Library Name: FHIRHelpers |
|
|
Logic Definition | Library Name: FHIRHelpers |
|
|
Logic Definition | Library Name: FHIRHelpers |
|
|
Logic Definition | Library Name: FHIRHelpers |
|
|
Logic Definition | Library Name: QICoreCommon |
|
|
Logic Definition | Library Name: QICoreCommon |
|
|
Logic Definition | Library Name: QICoreCommon |
|
|
Logic Definition | Library Name: QICoreCommon |
|
|
Logic Definition | Library Name: QICoreCommon |
|
|
Logic Definition | Library Name: QICoreCommon |
|
|
Logic Definition | Library Name: QICoreCommon |
|
|
Logic Definition | Library Name: CQMCommon |
|
|
Logic Definition | Library Name: CQMCommon |
|
|
Logic Definition | Library Name: CQMCommon |
|
|
Logic Definition | Library Name: CQMCommon |
|
|
Logic Definition | Library Name: CQMCommon |
|
|
Terminology | |
Code System |
Description: Code system SNOMEDCT
Resource: SNOMED CT (all versions) Canonical URL: http://snomed.info/sct |
Code System |
Description: Code system Diagnosis Type
Resource: Example Diagnosis Type Codes Canonical URL: http://terminology.hl7.org/CodeSystem/ex-diagnosistype |
Code System |
Description: Code system MedicationRequestCategory
Resource: MedicationRequest Category Codes Canonical URL: http://terminology.hl7.org/CodeSystem/medicationrequest-category |
Code System |
Description: Code system TaskCode
Resource: Task Codes Canonical URL: http://hl7.org/fhir/CodeSystem/task-code |
Value Set |
Description: Value set Nonelective Inpatient Encounter
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.424
Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.424 |
Value Set |
Description: Value set Ischemic Stroke
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.247
Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.247 |
Value Set |
Description: Value set Antithrombotic Therapy for Ischemic Stroke
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.62
Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.62 |
Value Set |
Description: Value set Payer Type
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3591
Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3591 |
Value Set |
Description: Value set Discharge To Acute Care Facility
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.87
Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.87 |
Value Set |
Description: Value set Left Against Medical Advice
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.308
Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.308 |
Value Set |
Description: Value set Patient Expired
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.309
Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.309 |
Value Set |
Description: Value set Discharged to Home for Hospice Care
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.209
Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.209 |
Value Set |
Description: Value set Discharged to Health Care Facility for Hospice Care
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.207
Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.207 |
Value Set |
Description: Value set Comfort Measures
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.33895.1.3.0.45
Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.33895.1.3.0.45 |
Value Set |
Description: Value set Observation Services
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.143
Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.143 |
Value Set |
Description: Value set Emergency Department Visit
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.292
Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.292 |
Value Set |
Description: Value set Medical Reason For Not Providing Treatment
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.473
Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.473 |
Value Set |
Description: Value set Patient Refusal
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.93
Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.93 |
Value Set |
Description: Value set Pharmacological Contraindications For Antithrombotic Therapy
Resource: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.52
Canonical URL: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.52 |
Direct Reference Code |
Display: Male (finding)
Code: 248153007 System: http://snomed.info/sct |
Direct Reference Code |
Display: Female (finding)
Code: 248152002 System: http://snomed.info/sct |
Direct Reference Code |
Display: Principal Diagnosis
Code: principal System: http://terminology.hl7.org/CodeSystem/ex-diagnosistype |
Direct Reference Code |
Display: Community
Code: community System: http://terminology.hl7.org/CodeSystem/medicationrequest-category |
Direct Reference Code |
Display: Discharge
Code: discharge System: http://terminology.hl7.org/CodeSystem/medicationrequest-category |
Direct Reference Code |
Code: fulfill
System: http://hl7.org/fhir/CodeSystem/task-code |
Dependencies | |
Dependency |
Description: Library SDE
Resource: SupplementalDataElementsversion: null5.1.000) Canonical URL: https://madie.cms.gov/Library/SupplementalDataElements|5.1.000 |
Dependency |
Description: Library FHIRHelpers
Resource: FHIRHelpersversion: null4.4.000) Canonical URL: https://madie.cms.gov/Library/FHIRHelpers|4.4.000 |
Dependency |
Description: Library TJC
Resource: TJCOverallversion: null8.24.000) Canonical URL: https://madie.cms.gov/Library/TJCOverall|8.24.000 |
Dependency |
Description: Library CQMCommon
Resource: CQMCommonversion: null4.1.000) Canonical URL: https://madie.cms.gov/Library/CQMCommon|4.1.000 |
Dependency |
Description: Library QICoreCommon
Resource: QICoreCommonversion: null4.0.000) Canonical URL: https://madie.cms.gov/Library/QICoreCommon|4.0.000 |
Data Requirements | |
Data Requirement |
Type: Patient
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-patient
Must Support Elements: extension, url, birthDate, birthDate.value |
Data Requirement |
Type: Encounter
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-encounter
Must Support Elements: type, status, status.value, period, diagnosis, diagnosis.code Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.143
|
Data Requirement |
Type: Encounter
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-encounter
Must Support Elements: type, status, status.value, period, diagnosis, diagnosis.code Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.292
|
Data Requirement |
Type: Encounter
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-encounter
Must Support Elements: type, period, diagnosis, diagnosis.code, hospitalization, hospitalization.dischargeDisposition Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.424
|
Data Requirement |
Type: Resource
Profile(s): Resource Must Support Elements: id, id.value |
Data Requirement |
Type: Claim
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-claim
Must Support Elements: status, status.value, use, use.value, item |
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-encounter-diagnosis
|
Data Requirement |
Type: Condition
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-condition-problems-health-concerns
|
Data Requirement |
Type: MedicationRequest
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationrequest
Must Support Elements: medication, status, status.value, intent, intent.value, authoredOn, authoredOn.value Code Filter(s): Path: medication ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.62
|
Data Requirement |
Type: MedicationRequest
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationrequest
Must Support Elements: medication.reference.value, status, status.value |
Data Requirement |
Type: MedicationRequest
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationrequest
Must Support Elements: medication, status, status.value, intent, intent.value, authoredOn, authoredOn.value Code Filter(s): Path: medication ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.52
|
Data Requirement |
Type: Task
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-taskrejected
Must Support Elements: focus, code, statusReason |
Data Requirement |
Type: Coverage
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-coverage
Must Support Elements: type, period Code Filter(s): Path: type ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3591
|
Data Requirement |
Type: ServiceRequest
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-servicerequest
Must Support Elements: code, status, status.value, intent, intent.value, doNotPerform, doNotPerform.value Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.33895.1.3.0.45
|
Data Requirement |
Type: Procedure
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-procedure
Must Support Elements: code, status, status.value Code Filter(s): Path: code ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.33895.1.3.0.45
|
Data Requirement |
Type: MedicationRequest
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medicationnotrequested
Must Support Elements: medication, reasonCode, status, status.value, intent, intent.value Code Filter(s): Path: medication ValueSet: http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.62
|
Data Requirement |
Type: Medication
Profile(s): http://hl7.org/fhir/us/qicore/StructureDefinition/qicore-medication
Must Support Elements: id.value, code |
Generated using version 0.4.8 of the sample-content-ig Liquid templates |